| Symbol | KPTI |
|---|---|
| Name | KARYOPHARM THERAPEUTICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 85 WELLS AVENUE,2ND FLOOR, NEWTON, Massachusetts, 02459, United States |
| Telephone | +1 617 658-0600 |
| Fax | — |
| — | |
| Website | https://www.karyopharm.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001503802 |
| Description | Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharms lead compound, XPOVIO(R) (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade(R) (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. Additional info from NASDAQ: |
2026-05-15 20:08
Poulton Stuart 🟡 adjusted position in 493 shares of Karyopharm Therapeutics Inc. (KPTI) at $9.50 Transaction Date: May 13, 2026 | Filing ID: 226697
Read more
2026-05-15 20:07
Rangwala Reshma 🟡 adjusted position in 539 shares of Karyopharm Therapeutics Inc. (KPTI) at $9.50 Transaction Date: May 13, 2026 | Filing ID: 226685
Read more
2026-05-15 20:05
Cheng Sohanya Roshan 🟡 adjusted position in 623 shares of Karyopharm Therapeutics Inc. (KPTI) at $9.50 Transaction Date: May 13, 2026 | Filing ID: 226652
Read more
2026-05-15 20:04
Abate Kristin 🟡 adjusted position in 68 shares of Karyopharm Therapeutics Inc. (KPTI) at $9.50 Transaction Date: May 13, 2026 | Filing ID: 226616
Read more
2026-05-15 20:03
Paulson Richard A. 🟡 adjusted position in 2.7K shares of Karyopharm Therapeutics Inc. (KPTI) at $9.50 Transaction Date: May 13, 2026 | Filing ID: 226613
Read more
2026-05-15 20:02
Mano Michael 🟡 adjusted position in 434 shares of Karyopharm Therapeutics Inc. (KPTI) at $9.50 Transaction Date: May 13, 2026 | Filing ID: 226604
Read more
2026-05-15 18:00
New Form SCHEDULE 13G - Karyopharm Therapeutics Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001193125-26-227136 <b>Size:</b> 152 KB
Read more
2026-05-15 15:59
New Form SCHEDULE 13G - Karyopharm Therapeutics Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001636587-26-000031 <b>Size:</b> 12 KB
Read more
2026-05-15 07:14
New Form EFFECT - Karyopharm Therapeutics Inc. <b>Filed:</b> 2026-05-14 <b>AccNo:</b> 9999999995-26-001655 <b>Size:</b> 1 KB
Read more
2026-05-15 07:14
New Form EFFECT - Karyopharm Therapeutics Inc. <b>Filed:</b> 2026-05-14 <b>AccNo:</b> 9999999995-26-001656 <b>Size:</b> 1 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07215832 | Karyopharm Expanded Access Program for Selinexor | — | Multiple Myeloma | Available | — | — | ClinicalTrials.gov |
| NCT07447817 | Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias | Phase2 | Myelofibrosis | Not_Yet_Recruiting | 2026-05-04 | 2030-05-24 | ClinicalTrials.gov |
| NCT07200102 | Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma | Phase1 | Multiple Myeloma | Recruiting | 2026-03-17 | 2031-03-31 | ClinicalTrials.gov |
| NCT07362225 | MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, an… | — | Polycythemia Vera | Recruiting | 2025-09-26 | 2035-09-08 | ClinicalTrials.gov |
| NCT06399640 | Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and… | Phase1 | Relapsed Myelodysplastic Syndrome | Recruiting | 2024-08-14 | 2027-10-01 | ClinicalTrials.gov |
| NCT05980806 | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibr… | Phase2 | Myelofibrosis | Recruiting | 2024-04-22 | 2028-10-01 | ClinicalTrials.gov |
| NCT05820763 | Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multi… | Phase2 | Multiple Myeloma | Withdrawn | 2024-01-05 | 2027-01-31 | ClinicalTrials.gov |
| NCT05983276 | Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standar… | Phase2 | Ovarian Cancer | Recruiting | 2023-11-16 | 2031-08-28 | ClinicalTrials.gov |
| NCT05597345 | Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple M… | Phase2 | Smoldering Multiple Myeloma | Recruiting | 2023-08-21 | 2025-12-31 | ClinicalTrials.gov |
| NCT05611931 | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p… | Phase3 | Endometrial Cancer | Recruiting | 2023-04-18 | 2028-01-01 | ClinicalTrials.gov |
| NCT05530421 | Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/… | Phase2 | Relapsed and Refractory Multiple Myeloma | Recruiting | 2023-03-26 | 2030-03-26 | ClinicalTrials.gov |
| NCT05170789 | Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myelo… | Phase2 | Relapsed Multiple Myeloma | Withdrawn | 2022-04-27 | 2022-04-27 | ClinicalTrials.gov |
| NCT05028348 | A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Vers… | Phase3 | Multiple Myeloma | Active_Not_Recruiting | 2022-04-19 | 2029-03-01 | ClinicalTrials.gov |
| NCT04843579 | Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dex… | Phase2 | Myeloma Multiple | Terminated | 2021-12-29 | 2022-12-30 | ClinicalTrials.gov |
| NCT04984330 | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Dis… | Early_Phase1 | Amyloid | Withdrawn | 2021-12-01 | 2024-06-01 | ClinicalTrials.gov |
| NCT04925193 | Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma | Phase2 | Multiple Myeloma in Relapse | Active_Not_Recruiting | 2021-11-18 | 2026-11-01 | ClinicalTrials.gov |
| NCT04898894 | Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric… | Phase1 | Acute Leukemia of Ambiguous Lineage in Relapse | Active_Not_Recruiting | 2021-11-15 | 2027-09-01 | ClinicalTrials.gov |
| NCT05093608 | SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Adva… | Phase1 | Hepatocellular Carcinoma | Terminated | 2021-11-03 | 2022-10-12 | ClinicalTrials.gov |
| NCT04782687 | Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | Phase2 | Multiple Myeloma | Active_Not_Recruiting | 2021-09-10 | 2026-05-31 | ClinicalTrials.gov |
| NCT04914845 | KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia | Phase1 | Acute Myeloid Leukemia | Completed | 2021-08-27 | 2025-10-22 | ClinicalTrials.gov |
| NCT04717700 | Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE… | Phase2 | Multiple Myeloma | Active_Not_Recruiting | 2021-08-18 | 2029-06-01 | ClinicalTrials.gov |
| NCT04854434 | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembro… | Phase2 | Metastatic Colorectal Cancer | Terminated | 2021-06-29 | 2022-06-24 | ClinicalTrials.gov |
| NCT04768881 | Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent… | Phase2 | Locally Advanced Unresectable or Metastatic Melanoma | Terminated | 2021-05-12 | 2023-09-22 | ClinicalTrials.gov |
| NCT04856189 | Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cispla… | Phase1 | Advanced Urothelial Carcinoma | Terminated | 2021-04-08 | 2024-02-13 | ClinicalTrials.gov |
| NCT04562870 | A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Partici… | Phase2 | Myelofibrosis | Active_Not_Recruiting | 2021-03-17 | 2026-09-01 | ClinicalTrials.gov |
| NCT04661137 | A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidom… | Phase2 | Multiple Myeloma | Suspended | 2021-03-16 | 2027-02-01 | ClinicalTrials.gov |
| NCT04562389 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | Phase3 | Myelofibrosis | Active_Not_Recruiting | 2021-03-11 | 2028-03-01 | ClinicalTrials.gov |
| NCT04607772 | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies I… | Phase1 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Withdrawn | 2020-11-18 | 2025-12-01 | ClinicalTrials.gov |
| NCT03880123 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | Phase1 | Liposarcoma | Withdrawn | 2020-11-01 | 2020-11-24 | ClinicalTrials.gov |
| NCT04519476 | Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalid… | Phase1 | Refractory Multiple Myeloma | Unknown | 2020-11-01 | 2023-12-29 | ClinicalTrials.gov |
| NCT04442022 | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without… | Phase2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | Active_Not_Recruiting | 2020-09-03 | 2026-12-01 | ClinicalTrials.gov |
| NCT04414475 | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory … | Phase2 | Multiple Myeloma, Refractory | Recruiting | 2020-07-01 | 2028-01-01 | ClinicalTrials.gov |
| NCT04421378 | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Dia… | Phase1 | Glioblastoma Multiforme | Terminated | 2020-06-08 | 2023-07-03 | ClinicalTrials.gov |
| NCT04355676 | Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in… | Phase2 | Coronavirus Infection | Withdrawn | 2020-04-30 | 2020-08-30 | ClinicalTrials.gov |
| NCT04349098 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe… | Phase2 | Coronavirus Infection | Completed | 2020-04-17 | 2020-10-05 | ClinicalTrials.gov |
| NCT04256707 | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor,… | Phase1 | Non-Small Cell Lung Carcinoma (NSCLC) | Completed | 2020-01-14 | 2024-07-31 | ClinicalTrials.gov |
| NCT03955783 | Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High … | Phase1 | Diffuse Large B-cell Lymphoma | Completed | 2019-06-21 | 2024-09-01 | ClinicalTrials.gov |
| NCT03627403 | Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors | Phase2 | Primary Myelofibrosis | Terminated | 2019-05-10 | 2025-03-05 | ClinicalTrials.gov |
| NCT03193437 | Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After P… | Phase2 | Thymoma | Terminated | 2018-04-03 | 2022-01-31 | ClinicalTrials.gov |
| NCT03095612 | Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung C… | Phase1 | Non-small Cell Lung Cancer | Terminated | 2018-03-22 | 2023-03-03 | ClinicalTrials.gov |
| NCT03555422 | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participan… | Phase3 | Endometrial Cancer | Completed | 2018-01-05 | 2025-04-03 | ClinicalTrials.gov |
| NCT03466827 | Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma | Phase2 | Thymoma | Unknown | 2017-10-12 | 2020-07-01 | ClinicalTrials.gov |
| NCT03191981 | Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Mult… | Phase1 | Myeloma Multiple | Withdrawn | 2017-08-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT02780609 | Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell T… | Phase1 | Multiple Myeloma | Completed | 2017-07-20 | 2021-02-23 | ClinicalTrials.gov |
| NCT03110562 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma | Phase3 | Multiple Myeloma | Completed | 2017-05-24 | 2022-05-12 | ClinicalTrials.gov |
| NCT03042819 | Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas | Phase1 | Soft Tissue Sarcoma | Completed | 2017-05-16 | 2021-06-30 | ClinicalTrials.gov |
| NCT02741388 | A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B… | Phase1 | B-cell Lymphoma | Completed | 2016-10-01 | 2021-09-29 | ClinicalTrials.gov |
| NCT02831686 | A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexametha… | Phase1 | Multiple Myeloma | Completed | 2016-07-01 | 2020-11-19 | ClinicalTrials.gov |
| NCT02702492 | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) | Phase1 | Solid Tumors | Terminated | 2016-06-08 | 2021-01-26 | ClinicalTrials.gov |
| NCT03071276 | Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refra… | Phase2 | Acute Myeloid Leukemia (AML) | Terminated | 2016-01-14 | 2019-04-30 | ClinicalTrials.gov |
| NCT02606461 | Selinexor in Advanced Liposarcoma | Phase2 | Dedifferentiated Liposarcoma | Completed | 2016-01-04 | 2021-10-26 | ClinicalTrials.gov |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With… | Phase1 | Relapsed/Refractory Multiple Myeloma (RRMM) | Completed | 2016-01-01 | 2024-12-23 | ClinicalTrials.gov |
| NCT02471911 | KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma | Phase1 | Diffuse Large B-Cell Lymphoma | Completed | 2015-12-11 | 2021-10-14 | ClinicalTrials.gov |
| NCT02530476 | Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KP… | Phase1 | Leukemia | Completed | 2015-12-08 | 2019-04-08 | ClinicalTrials.gov |
| NCT02628704 | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexa… | Phase2 | Multiple Myeloma | Withdrawn | 2015-12-01 | 2018-06-01 | ClinicalTrials.gov |
| NCT02431351 | Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myel… | Phase2 | Myelodysplastic Syndrome | Withdrawn | 2015-11-01 | 2019-05-01 | ClinicalTrials.gov |
| NCT02436707 | Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressiv… | Phase2 | Lymphoma | Active_Not_Recruiting | 2015-10-27 | 2026-12-31 | ClinicalTrials.gov |
| NCT02343042 | Selinexor and Backbone Treatments of Multiple Myeloma Patients | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2015-10-01 | 2027-04-01 | ClinicalTrials.gov |
| NCT02536495 | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squam… | Phase1 | Recurrent Squamous Cell Lung Carcinoma | Withdrawn | 2015-09-01 | — | ClinicalTrials.gov |
| NCT02402764 | Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Canc… | Phase2 | Breast Cancer | Completed | 2015-07-08 | 2019-06-06 | ClinicalTrials.gov |
| NCT02389543 | Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refrac… | Phase1 | Multiple Myeloma | Withdrawn | 2015-07-01 | 2018-02-01 | ClinicalTrials.gov |
| NCT02403310 | A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untrea… | Phase1 | Leukemia | Completed | 2015-06-18 | 2021-02-01 | ClinicalTrials.gov |
| NCT02416908 | Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia | Phase1 | Acute Myeloid Leukemia | Completed | 2015-06-16 | 2019-06-21 | ClinicalTrials.gov |
| NCT02303392 | Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chroni… | Phase1 | Prolymphocytic Leukemia | Completed | 2015-06-09 | 2022-04-18 | ClinicalTrials.gov |
| NCT02336815 | Selinexor Treatment of Refractory Myeloma | Phase2 | Multiple Myeloma | Completed | 2015-05-26 | 2019-07-26 | ClinicalTrials.gov |
| NCT02431364 | Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults | Phase1 | Healthy | Terminated | 2015-05-26 | 2015-10-01 | ClinicalTrials.gov |
| NCT02299518 | Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acu… | Phase1 | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Completed | 2015-05-18 | 2018-03-06 | ClinicalTrials.gov |
| NCT02351505 | Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer | Phase2 | Recurrent Small Cell Lung Carcinoma | Terminated | 2015-05-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02384850 | Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic C… | Phase1 | Colorectal Neoplasm | Terminated | 2015-03-01 | 2017-03-09 | ClinicalTrials.gov |
| NCT02314247 | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-c… | Phase2 | Peripheral T-cell Lymphoma (PTCL) | Terminated | 2015-02-01 | 2016-02-01 | ClinicalTrials.gov |
| NCT02367690 | Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-3… | Phase1 | Diabetic Foot Ulcers | Withdrawn | 2015-01-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02137356 | Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Loc… | Phase1 | Rectal Neoplasms | Unknown | 2014-12-01 | 2017-09-01 | ClinicalTrials.gov |
| NCT02138786 | Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation | Phase2 | Richter's Transformation | Terminated | 2014-11-14 | 2016-08-31 | ClinicalTrials.gov |
| NCT02227251 | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell L… | Phase2 | Diffuse Large B-cell Lymphoma | Active_Not_Recruiting | 2014-11-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT02186834 | Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multi… | Phase1 | Multiple Myeloma | Completed | 2014-09-23 | 2018-03-14 | ClinicalTrials.gov |
| NCT02213133 | Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas | Phase2 | Squamous Cell Carcinoma | Terminated | 2014-09-22 | 2015-12-10 | ClinicalTrials.gov |
| NCT02249091 | A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With R… | Phase2 | Acute Myeloid Leukemia (Relapsed/Refractory) | Completed | 2014-09-01 | 2018-07-31 | ClinicalTrials.gov |
| NCT05177276 | Selinexor Combination Ph 1 Study | Phase1 | Solid Tumor Malignancy | Withdrawn | 2014-09-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02228525 | Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients Wi… | Phase2 | Myelodysplastic Syndromes | Completed | 2014-08-27 | 2021-04-06 | ClinicalTrials.gov |
| NCT02120222 | Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Remov… | Phase1 | Recurrent Melanoma | Completed | 2014-08-22 | 2018-04-08 | ClinicalTrials.gov |
| NCT02250885 | KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors | Phase2 | Carcinoma, Neuroendocrine | Completed | 2014-08-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02212561 | Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relaps… | Phase1 | Acute Myeloid Leukemia (AML) | Completed | 2014-08-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02146833 | SHIP (Selinexor in Hormone Insensitive Prostate Cancer) | Phase2 | Prostate Cancer | Terminated | 2014-05-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02025985 | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Mali… | Phase2 | Ovarian Carcinoma | Completed | 2014-04-09 | 2017-03-29 | ClinicalTrials.gov |
| NCT01986348 | Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants… | Phase2 | Glioblastoma | Terminated | 2014-03-03 | 2020-01-23 | ClinicalTrials.gov |
| NCT02091245 | Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapse… | Phase1 | Relapsed Acute Lymphoblastic Leukemia (ALL) | Active_Not_Recruiting | 2014-03-01 | 2026-06-01 | ClinicalTrials.gov |
| NCT02093403 | Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute… | Phase1 | Acute Myeloid Leukemia | Completed | 2014-03-01 | 2016-11-26 | ClinicalTrials.gov |
| NCT02088541 | Selinexor (KPT-330) in Older Patients With Relapsed AML | Phase2 | Acute Myeloid Leukemia (AML) | Completed | 2014-03-01 | 2018-01-08 | ClinicalTrials.gov |
| NCT02078349 | Phase I Study of KPT330 in Asian Patients | Phase1 | Solid Tumors | Completed | 2014-02-01 | 2020-03-20 | ClinicalTrials.gov |
| NCT01896505 | A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 … | Phase1 | Sarcoma | Completed | 2013-07-30 | 2016-10-21 | ClinicalTrials.gov |
| NCT01607892 | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Pat… | Phase1 | Hematological Malignancies | Completed | 2012-07-23 | 2015-10-13 | ClinicalTrials.gov |
| NCT01607905 | Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Sol… | Phase1 | Solid Tumor | Completed | 2012-06-18 | 2016-03-15 | ClinicalTrials.gov |
Total clinical trials: 92
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Selinexor | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT02227251 |
| Placebo matching for Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Cisplatin (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Dexamethasone (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Gemcitabine (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Rituximab (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Placebo matching for Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Placebo matching for Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Cisplatin (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Dexamethasone (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Gemcitabine (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Rituximab (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Placebo matching for Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT02227251 |
| Placebo matching for Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Cisplatin (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Dexamethasone (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Gemcitabine (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Rituximab (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Placebo matching for Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT02227251 |
| Placebo matching for Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Cisplatin (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Dexamethasone (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Gemcitabine (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Rituximab (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Placebo matching for Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT02227251 |
| Placebo matching for Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Cisplatin (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Dexamethasone (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Gemcitabine (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Rituximab (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Placebo matching for Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT02227251 |
| Placebo matching for Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Cisplatin (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Dexamethasone (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Gemcitabine (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Rituximab (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Placebo matching for Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT02227251 |
| Placebo matching for Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Cisplatin (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Dexamethasone (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Gemcitabine (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Rituximab (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Placebo matching for Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT02227251 |
| Placebo matching for Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Cisplatin (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Dexamethasone (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Gemcitabine (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Rituximab (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Placebo matching for Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT02227251 |
| Placebo matching for Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Cisplatin (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Dexamethasone (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Gemcitabine (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Rituximab (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Placebo matching for Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04442022 |
| Mezigdomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Belantamab Mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Clarithromycin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Elotuzumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Daratumumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Selinexor | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Mezigdomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Belantamab Mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Clarithromycin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Elotuzumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Daratumumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Selinexor | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Mezigdomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Belantamab Mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Clarithromycin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Elotuzumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Daratumumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Selinexor | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Mezigdomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Belantamab Mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Clarithromycin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Elotuzumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Daratumumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Selinexor | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Mezigdomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Belantamab Mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Clarithromycin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Elotuzumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Daratumumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Selinexor | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Mezigdomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Belantamab Mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Clarithromycin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Elotuzumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Daratumumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Selinexor | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Mezigdomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Belantamab Mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Clarithromycin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Elotuzumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Daratumumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Selinexor | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Mezigdomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Belantamab Mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Clarithromycin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Elotuzumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Daratumumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Selinexor | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Mezigdomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Belantamab Mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Clarithromycin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Elotuzumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Daratumumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Selinexor | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Mezigdomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Belantamab Mafodotin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Clarithromycin | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Elotuzumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Daratumumab | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Selinexor | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT02343042 |
| Atezolizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT05093608 |
| Bevacizumab | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT05093608 |
| Selinexor Pill | Other | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT05093608 |
| Selinexor | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT05983276 |
| Paclitaxel | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT05983276 |
| Carboplatin | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT05983276 |
| Decitabine | Other | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT05983276 |
| Dexamethasone | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT03110562 |
| Bortezomib | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT03110562 |
| Selinexor | Other | Phase PHASE3 | Multiple Myeloma | COMPLETED | NCT03110562 |
| dose-escalated selinexor treatment | Drug | Phase PHASE1 | Rectal Neoplasms | UNKNOWN | NCT02137356 |
| standard dose capecitabine | Other | Phase PHASE1 | Rectal Neoplasms | UNKNOWN | NCT02137356 |
| standard dose pelvic radiation therapy | Drug | Phase PHASE1 | Rectal Neoplasms | UNKNOWN | NCT02137356 |
| Selinexor | Other | Phase PHASE1 | Recurrent Squamous Cell Lung Carcinoma | WITHDRAWN | NCT02536495 |
| Pharmacological Study | Other | Phase PHASE1 | Recurrent Squamous Cell Lung Carcinoma | WITHDRAWN | NCT02536495 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | Recurrent Squamous Cell Lung Carcinoma | WITHDRAWN | NCT02536495 |
| Docetaxel | Other | Phase PHASE1 | Recurrent Squamous Cell Lung Carcinoma | WITHDRAWN | NCT02536495 |
| Pharmacological Study | Other | Phase PHASE2 | Recurrent Small Cell Lung Carcinoma | TERMINATED | NCT02351505 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Recurrent Small Cell Lung Carcinoma | TERMINATED | NCT02351505 |
| Selinexor | Other | Phase PHASE2 | Recurrent Small Cell Lung Carcinoma | TERMINATED | NCT02351505 |
| Pembrolizumab | Other | Phase PHASE1 | Myeloma Multiple | WITHDRAWN | NCT03191981 |
| Lenalidomide | Other | Phase PHASE1 | Myeloma Multiple | WITHDRAWN | NCT03191981 |
| Cyclophosphamide | Other | Phase PHASE1 | Myeloma Multiple | WITHDRAWN | NCT03191981 |
| laboratory biomarker analysis | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02093403 |
| pharmacological study | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02093403 |
| selinexor | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02093403 |
| decitabine | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02093403 |
| Selinexor | Other | Phase PHASE2 | Thymoma | UNKNOWN | NCT03466827 |
| Selinexor | Other | Phase PHASE2 | Carcinoma, Neuroendocrine | COMPLETED | NCT02250885 |
| Bone marrow biopsy | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02416908 |
| Cytarabine | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02416908 |
| G-CSF | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02416908 |
| Cladribine | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02416908 |
| Selinexor | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02416908 |
| methotrexate/hydrocortisone/cytarabine | Other | Phase PHASE1 | Acute Myeloid Leukemia (AML) | COMPLETED | NCT02212561 |
| Cytarabine | Other | Phase PHASE1 | Acute Myeloid Leukemia (AML) | COMPLETED | NCT02212561 |
| Fludarabine | Other | Phase PHASE1 | Acute Myeloid Leukemia (AML) | COMPLETED | NCT02212561 |
| Selinexor | Other | Phase PHASE1 | Acute Myeloid Leukemia (AML) | COMPLETED | NCT02212561 |
| Sorafenib | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT02530476 |
| Selinexor | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT02530476 |
| methotrexate/hydrocortisone/cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia (AML) | TERMINATED | NCT03071276 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia (AML) | TERMINATED | NCT03071276 |
| Fludarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia (AML) | TERMINATED | NCT03071276 |
| Selinexor | Other | Phase PHASE2 | Acute Myeloid Leukemia (AML) | TERMINATED | NCT03071276 |
| KPT-330 | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT02078349 |
| Selinexor | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02402764 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02831686 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02831686 |
| Selinexor | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02831686 |
| Ixazomib | Other | Phase PHASE1 | Liposarcoma | WITHDRAWN | NCT03880123 |
| Selinexor | Other | Phase PHASE1 | Liposarcoma | WITHDRAWN | NCT03880123 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia (Relapsed/Refractory) | COMPLETED | NCT02249091 |
| Idarubicin | Other | Phase PHASE2 | Acute Myeloid Leukemia (Relapsed/Refractory) | COMPLETED | NCT02249091 |
| Selinexor | Other | Phase PHASE2 | Acute Myeloid Leukemia (Relapsed/Refractory) | COMPLETED | NCT02249091 |
| Gemcitabine | Other | Phase PHASE1 | B-cell Lymphoma | COMPLETED | NCT02741388 |
| Cytarabine | Other | Phase PHASE1 | B-cell Lymphoma | COMPLETED | NCT02741388 |
| Cisplatin | Other | Phase PHASE1 | B-cell Lymphoma | COMPLETED | NCT02741388 |
| Oxaliplatin | Other | Phase PHASE1 | B-cell Lymphoma | COMPLETED | NCT02741388 |
| Dexamethasone | Other | Phase PHASE1 | B-cell Lymphoma | COMPLETED | NCT02741388 |
| Rituximab | Other | Phase PHASE1 | B-cell Lymphoma | COMPLETED | NCT02741388 |
| selinexor | Other | Phase PHASE1 | B-cell Lymphoma | COMPLETED | NCT02741388 |
| Doxorubicin | Other | Phase PHASE1 | Soft Tissue Sarcoma | COMPLETED | NCT03042819 |
| Selinexor | Other | Phase PHASE1 | Soft Tissue Sarcoma | COMPLETED | NCT03042819 |
| Irinotecan | Other | Phase PHASE1 | Solid Tumor Malignancy | WITHDRAWN | NCT05177276 |
| Selinexor | Other | Phase PHASE1 | Solid Tumor Malignancy | WITHDRAWN | NCT05177276 |
| selinexor (KPT-330) | Other | Phase PHASE2 | Myelodysplastic Syndromes | COMPLETED | NCT02228525 |
| Folinic Acid | Other | Phase PHASE1 | Colorectal Neoplasm | TERMINATED | NCT02384850 |
| 5-FU | Other | Phase PHASE1 | Colorectal Neoplasm | TERMINATED | NCT02384850 |
| Oxaliplatin | Other | Phase PHASE1 | Colorectal Neoplasm | TERMINATED | NCT02384850 |
| Selinexor | Other | Phase PHASE1 | Colorectal Neoplasm | TERMINATED | NCT02384850 |
| Dexamethasone | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT02471911 |
| Ifosfamide | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT02471911 |
| Carboplatin | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT02471911 |
| Etoposide | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT02471911 |
| Rituximab | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT02471911 |
| KPT-330 | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT02471911 |
| Elotuzumab, Selinexor, and Dexamethasone (ESd) | Other | Phase PHASE2 | Relapsed Multiple Myeloma | WITHDRAWN | NCT05170789 |
| Cytarabine | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT02403310 |
| Daunorubicin | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT02403310 |
| Selinexor | Other | Phase PHASE1 | Leukemia | COMPLETED | NCT02403310 |
| Fosaprepitant | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02780609 |
| Autologous Hematopoietic Cell Transplantation (HCT) | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02780609 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02780609 |
| Melphalan | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02780609 |
| Selinexor | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02780609 |
| Dexamethasone | Other | Phase EARLY_PHASE1 | Amyloid | WITHDRAWN | NCT04984330 |
| Selinexor | Other | Phase EARLY_PHASE1 | Amyloid | WITHDRAWN | NCT04984330 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02186834 |
| Liposomal doxorubicin | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02186834 |
| Selinexor | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02186834 |
| Selinexor | Other | Phase PHASE2 | Coronavirus Infection | WITHDRAWN | NCT04355676 |
| Placebo | Other | Phase PHASE2 | Coronavirus Infection | COMPLETED | NCT04349098 |
| Selinexor | Other | Phase PHASE2 | Coronavirus Infection | COMPLETED | NCT04349098 |
| Placebo | Other | Phase PHASE1 | Healthy | TERMINATED | NCT02431364 |
| Verdinexor | Other | Phase PHASE1 | Healthy | TERMINATED | NCT02431364 |
| Vehicle Gel | Other | Phase PHASE1 | Diabetic Foot Ulcers | WITHDRAWN | NCT02367690 |
| Standard-of-Care | Other | Phase PHASE1 | Diabetic Foot Ulcers | WITHDRAWN | NCT02367690 |
| Selinexor | Other | Phase PHASE1 | Diabetic Foot Ulcers | WITHDRAWN | NCT02367690 |
| Placebo | Other | Phase PHASE2 | Dedifferentiated Liposarcoma | COMPLETED | NCT02606461 |
| Selinexor | Other | Phase PHASE2 | Dedifferentiated Liposarcoma | COMPLETED | NCT02606461 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT02628704 |
| carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT02628704 |
| Placebo (for selinexor) | Other | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT02628704 |
| Selinexor | Other | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT02628704 |
| Selinexor | Other | Phase PHASE2 | Myelodysplastic Syndrome | WITHDRAWN | NCT02431351 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | WITHDRAWN | NCT02389543 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | WITHDRAWN | NCT02389543 |
| Selinexor | Other | Phase PHASE1 | Multiple Myeloma | WITHDRAWN | NCT02389543 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02336815 |
| Selinexor | Other | Phase PHASE2 | Multiple Myeloma | COMPLETED | NCT02336815 |
| Selinexor | Other | Phase PHASE2 | Peripheral T-cell Lymphoma (PTCL) | TERMINATED | NCT02314247 |
| Selinexor (KPT-330) | Other | Phase PHASE2 | Squamous Cell Carcinoma | TERMINATED | NCT02213133 |
| Selinexor | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT02146833 |
| selinexor | Other | Phase PHASE2 | Richter's Transformation | TERMINATED | NCT02138786 |
| Ara-C | Other | Phase PHASE2 | Acute Myeloid Leukemia (AML) | COMPLETED | NCT02088541 |
| Hydroxyurea | Other | Phase PHASE2 | Acute Myeloid Leukemia (AML) | COMPLETED | NCT02088541 |
| Selinexor | Other | Phase PHASE2 | Acute Myeloid Leukemia (AML) | COMPLETED | NCT02088541 |
| Selinexor | Other | Phase PHASE2 | Ovarian Carcinoma | COMPLETED | NCT02025985 |
| Selinexor | Other | Phase PHASE2 | Glioblastoma | TERMINATED | NCT01986348 |
| Acetaminophen | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT01607905 |
| Selinexor | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT01607905 |
| KPT-330 | Other | Phase PHASE1 | Hematological Malignancies | COMPLETED | NCT01607892 |
| Open Label Selinexor | Other | Phase PHASE2 | Thymoma | TERMINATED | NCT03193437 |
| Correlative studies | Other | Phase PHASE1 | Recurrent Melanoma | COMPLETED | NCT02120222 |
| selinexor | Other | Phase PHASE1 | Recurrent Melanoma | COMPLETED | NCT02120222 |
| pharmacological study | Other | Phase PHASE1 | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | COMPLETED | NCT02299518 |
| laboratory biomarker analysis | Other | Phase PHASE1 | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | COMPLETED | NCT02299518 |
| selinexor | Other | Phase PHASE1 | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | COMPLETED | NCT02299518 |
| cytarabine | Other | Phase PHASE1 | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | COMPLETED | NCT02299518 |
| etoposide | Other | Phase PHASE1 | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | COMPLETED | NCT02299518 |
| mitoxantrone hydrochloride | Other | Phase PHASE1 | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | COMPLETED | NCT02299518 |
| Dexamethasone | Other | Phase PHASE2 | Myeloma Multiple | TERMINATED | NCT04843579 |
| Pomalidomide | Other | Phase PHASE2 | Myeloma Multiple | TERMINATED | NCT04843579 |
| Clarithromycin | Other | Phase PHASE2 | Myeloma Multiple | TERMINATED | NCT04843579 |
| Selinexor | Other | Phase PHASE2 | Myeloma Multiple | TERMINATED | NCT04843579 |
| Methylprednisolone | Other | Phase PHASE1 | Refractory Multiple Myeloma | UNKNOWN | NCT04519476 |
| Lenalidomide | Other | Phase PHASE1 | Refractory Multiple Myeloma | UNKNOWN | NCT04519476 |
| Selinexor | Other | Phase PHASE1 | Refractory Multiple Myeloma | UNKNOWN | NCT04519476 |
| Tipiracil | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT04854434 |
| Trifluridine | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT04854434 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT04854434 |
| Selinexor | Other | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT04854434 |
| KCP-330 | Other | Phase PHASE1 | Sarcoma | COMPLETED | NCT01896505 |
| Docetaxel | Other | Phase PHASE1 | Non-small Cell Lung Cancer | TERMINATED | NCT03095612 |
| Selinexor | Other | Phase PHASE1 | Non-small Cell Lung Cancer | TERMINATED | NCT03095612 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT05820763 |
| Lenalidomide | Other | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT05820763 |
| Selinexor | Other | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT05820763 |
| Pembrolizumab | Other | Phase PHASE2 | Locally Advanced Unresectable or Metastatic Melanoma | TERMINATED | NCT04768881 |
| Selinexor | Other | Phase PHASE2 | Locally Advanced Unresectable or Metastatic Melanoma | TERMINATED | NCT04768881 |
| Selinexor | Other | Phase PHASE1 | Diffuse Large B-cell Lymphoma | COMPLETED | NCT03955783 |
| Venetoclax | Other | Phase PHASE1 | Diffuse Large B-cell Lymphoma | COMPLETED | NCT03955783 |
| Nivolumab | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT02702492 |
| Niacin ER | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT02702492 |
| KPT-9274 | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT02702492 |
| Carmustine | Other | Phase PHASE1 | Glioblastoma Multiforme | TERMINATED | NCT04421378 |
| TTField | Other | Phase PHASE1 | Glioblastoma Multiforme | TERMINATED | NCT04421378 |
| Bevacizumab | Other | Phase PHASE1 | Glioblastoma Multiforme | TERMINATED | NCT04421378 |
| Standard Fractionated Radiation therapy (RT) | Drug | Phase PHASE1 | Glioblastoma Multiforme | TERMINATED | NCT04421378 |
| Lomustine (CCNU) | Other | Phase PHASE1 | Glioblastoma Multiforme | TERMINATED | NCT04421378 |
| Temozolomide (TMZ) | Other | Phase PHASE1 | Glioblastoma Multiforme | TERMINATED | NCT04421378 |
| Selinexor | Other | Phase PHASE1 | Glioblastoma Multiforme | TERMINATED | NCT04421378 |
| Lenalidomide | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04782687 |
| Daratumumab | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04782687 |
| Dexamethasone Oral | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04782687 |
| Selinexor | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04782687 |
| Selinexor | Other | Phase PHASE2 | Smoldering Multiple Myeloma | RECRUITING | NCT05597345 |
| Dexamethasone Oral | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04717700 |
| Lenalidomide capsule | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04717700 |
| Bortezomib Injection | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04717700 |
| Selinexor 20 MG Oral Tablet | Other | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04717700 |
| Selinexor 60 mg | Other | Phase PHASE1 | Non-Small Cell Lung Carcinoma (NSCLC) | COMPLETED | NCT04256707 |
| Selinexor 80 mg | Other | Phase PHASE1 | Non-Small Cell Lung Carcinoma (NSCLC) | COMPLETED | NCT04256707 |
| Selinexor 40 mg | Other | Phase PHASE1 | Non-Small Cell Lung Carcinoma (NSCLC) | COMPLETED | NCT04256707 |
| FOLFIRI | Other | Phase PHASE1 | Non-Small Cell Lung Carcinoma (NSCLC) | COMPLETED | NCT04256707 |
| Pembrolizumab | Other | Phase PHASE1 | Non-Small Cell Lung Carcinoma (NSCLC) | COMPLETED | NCT04256707 |
| Docetaxel | Other | Phase PHASE1 | Non-Small Cell Lung Carcinoma (NSCLC) | COMPLETED | NCT04256707 |
| Selinexor 100 mg | Other | Phase PHASE1 | Non-Small Cell Lung Carcinoma (NSCLC) | COMPLETED | NCT04256707 |
| Dexamethasone | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma (RRMM) | COMPLETED | NCT02649790 |
| ASTX727 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma (RRMM) | COMPLETED | NCT02649790 |
| KPT-8602 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma (RRMM) | COMPLETED | NCT02649790 |
| Biospecimen Collection | Other | Phase PHASE1 | Relapsed Myelodysplastic Syndrome | RECRUITING | NCT06399640 |
| Bone Marrow Aspiration and Biopsy | Other | Phase PHASE1 | Relapsed Myelodysplastic Syndrome | RECRUITING | NCT06399640 |
| Venetoclax | Other | Phase PHASE1 | Relapsed Myelodysplastic Syndrome | RECRUITING | NCT06399640 |
| Eltanexor | Other | Phase PHASE1 | Relapsed Myelodysplastic Syndrome | RECRUITING | NCT06399640 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | Prolymphocytic Leukemia | COMPLETED | NCT02303392 |
| Pharmacological Study | Other | Phase PHASE1 | Prolymphocytic Leukemia | COMPLETED | NCT02303392 |
| Ibrutinib | Other | Phase PHASE1 | Prolymphocytic Leukemia | COMPLETED | NCT02303392 |
| Selinexor | Other | Phase PHASE1 | Prolymphocytic Leukemia | COMPLETED | NCT02303392 |
| Selinexor | Other | Phase PHASE2 | Primary Myelofibrosis | TERMINATED | NCT03627403 |
| Matching Placebo for selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Selinexor | Other | Phase PHASE2 | Diffuse Large B-cell Lymphoma | RECRUITING | NCT02227251 |
| Oxaliplatin | Other | Phase PHASE1 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT04607772 |
| Gemcitabine | Other | Phase PHASE1 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT04607772 |
| Venetoclax | Other | Phase PHASE1 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT04607772 |
| Tafasitamab | Other | Phase PHASE1 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT04607772 |
| Lenalidomide | Other | Phase PHASE1 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT04607772 |
| Ibrutinib | Other | Phase PHASE1 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT04607772 |
| Polatuzumab Vedotin | Other | Phase PHASE1 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT04607772 |
| Bendamustine | Other | Phase PHASE1 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT04607772 |
| Rituximab | Other | Phase PHASE1 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT04607772 |
| Selinexor | Other | Phase PHASE1 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT04607772 |
| Physician's Choice Treatment | Drug | Phase PHASE2 | Myelofibrosis | ACTIVE_NOT_RECRUITING | NCT04562870 |
| Selinexor | Other | Phase PHASE2 | Myelofibrosis | ACTIVE_NOT_RECRUITING | NCT04562870 |
| Placebo matching for Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | RECRUITING | NCT04442022 |
| Selinexor (continuous therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | RECRUITING | NCT04442022 |
| Cisplatin (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | RECRUITING | NCT04442022 |
| Dexamethasone (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | RECRUITING | NCT04442022 |
| Gemcitabine (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | RECRUITING | NCT04442022 |
| Rituximab (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | RECRUITING | NCT04442022 |
| Placebo matching for Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | RECRUITING | NCT04442022 |
| Selinexor (combination therapy) | Drug | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | RECRUITING | NCT04442022 |
| KPT-330 | Other | Phase PHASE1 | Relapsed Acute Lymphoblastic Leukemia (ALL) | ACTIVE_NOT_RECRUITING | NCT02091245 |
| Dexamethasone Oral | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05028348 |
| Pomalidomide | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05028348 |
| Elotuzumab | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05028348 |
| Selinexor | Other | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05028348 |
| Mezigdomide | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT02343042 |
| Belantamab Mafodotin | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT02343042 |
| Clarithromycin | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT02343042 |
| Elotuzumab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT02343042 |
| Ixazomib | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT02343042 |
| Carfilzomib | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT02343042 |
| Daratumumab | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT02343042 |
| Bortezomib | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT02343042 |
| Pomalidomide | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT02343042 |
| Lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT02343042 |
| Dexamethasone | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT02343042 |
| Selinexor | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT02343042 |
| KPT-9274 | Other | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT04914845 |
| Selinexor | Other | Phase PHASE1 | Advanced Urothelial Carcinoma | TERMINATED | NCT04856189 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Urothelial Carcinoma | TERMINATED | NCT04856189 |
| Bortezomib | Other | Phase PHASE2 | Multiple Myeloma, Refractory | RECRUITING | NCT04414475 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma, Refractory | RECRUITING | NCT04414475 |
| Selinexor | Other | Phase PHASE2 | Multiple Myeloma, Refractory | RECRUITING | NCT04414475 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma | SUSPENDED | NCT04661137 |
| Daratumumab | Other | Phase PHASE2 | Multiple Myeloma | SUSPENDED | NCT04661137 |
| Pomalidomide | Other | Phase PHASE2 | Multiple Myeloma | SUSPENDED | NCT04661137 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma | SUSPENDED | NCT04661137 |
| Selinexor 100 MG | Other | Phase PHASE2 | Multiple Myeloma | SUSPENDED | NCT04661137 |
| Selinexor 80 MG | Other | Phase PHASE2 | Multiple Myeloma | SUSPENDED | NCT04661137 |
| Selinexor 60 MG | Other | Phase PHASE2 | Multiple Myeloma | SUSPENDED | NCT04661137 |
| Momelotinib | Other | Phase PHASE2 | Myelofibrosis | RECRUITING | NCT05980806 |
| Pacritinib | Other | Phase PHASE2 | Myelofibrosis | RECRUITING | NCT05980806 |
| Ruxolitinib | Other | Phase PHASE2 | Myelofibrosis | RECRUITING | NCT05980806 |
| Selinexor 40 mg | Other | Phase PHASE2 | Myelofibrosis | RECRUITING | NCT05980806 |
| Selinexor 60 mg | Other | Phase PHASE2 | Myelofibrosis | RECRUITING | NCT05980806 |
| Dexamethasone | Other | Phase PHASE2 | Relapsed and Refractory Multiple Myeloma | RECRUITING | NCT05530421 |
| Venetoclax | Other | Phase PHASE2 | Relapsed and Refractory Multiple Myeloma | RECRUITING | NCT05530421 |
| Selinexor | Other | Phase PHASE2 | Relapsed and Refractory Multiple Myeloma | RECRUITING | NCT05530421 |
| selinexor | Other | Preclinical | Multiple Myeloma | AVAILABLE | NCT07215832 |
| Selinexor | Other | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT07200102 |
| Dexamethasone | Other | Phase PHASE2 | Multiple Myeloma in Relapse | ACTIVE_NOT_RECRUITING | NCT04925193 |
| Carfilzomib | Other | Phase PHASE2 | Multiple Myeloma in Relapse | ACTIVE_NOT_RECRUITING | NCT04925193 |
| Daratumumab | Other | Phase PHASE2 | Multiple Myeloma in Relapse | ACTIVE_NOT_RECRUITING | NCT04925193 |
| Pomalidomide | Other | Phase PHASE2 | Multiple Myeloma in Relapse | ACTIVE_NOT_RECRUITING | NCT04925193 |
| Selinexor | Other | Phase PHASE2 | Multiple Myeloma in Relapse | ACTIVE_NOT_RECRUITING | NCT04925193 |
| Ruxolitinib | Other | Phase PHASE3 | Myelofibrosis | ACTIVE_NOT_RECRUITING | NCT04562389 |
| Placebo | Other | Phase PHASE3 | Myelofibrosis | ACTIVE_NOT_RECRUITING | NCT04562389 |
| Selinexor | Other | Phase PHASE3 | Myelofibrosis | ACTIVE_NOT_RECRUITING | NCT04562389 |
| Matching placebo for selinexor | Other | Phase PHASE3 | Endometrial Cancer | COMPLETED | NCT03555422 |
| Selinexor | Other | Phase PHASE3 | Endometrial Cancer | COMPLETED | NCT03555422 |
| Selinexor | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT02436707 |
| G-CSF | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT02436707 |
| Etoposide | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT02436707 |
| Cyclophosphamide | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT02436707 |
| Mesna | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT02436707 |
| Cisplatin | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT02436707 |
| Dexamethasone | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT02436707 |
| Gemcitabine | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT02436707 |
| Rituximab | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT02436707 |
| Ibrutinib | Other | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT02436707 |
| methotrexate/hydrocortisone/cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Methotrexate | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Filgrastim | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Fludarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Selinexor | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Venetoclax | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| methotrexate/hydrocortisone/cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Methotrexate | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Filgrastim | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Fludarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Selinexor | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Venetoclax | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| methotrexate/hydrocortisone/cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Methotrexate | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Filgrastim | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Fludarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Selinexor | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Venetoclax | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| methotrexate/hydrocortisone/cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Methotrexate | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Filgrastim | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Fludarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Selinexor | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Venetoclax | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| methotrexate/hydrocortisone/cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Methotrexate | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Filgrastim | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Fludarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Selinexor | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Venetoclax | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| methotrexate/hydrocortisone/cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Methotrexate | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Filgrastim | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Fludarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Selinexor | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Venetoclax | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| methotrexate/hydrocortisone/cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Methotrexate | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Filgrastim | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Fludarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Selinexor | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Venetoclax | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| methotrexate/hydrocortisone/cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Methotrexate | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Filgrastim | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Fludarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Selinexor | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Venetoclax | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| methotrexate/hydrocortisone/cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Methotrexate | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Filgrastim | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Fludarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Selinexor | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Venetoclax | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| methotrexate/hydrocortisone/cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Methotrexate | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Filgrastim | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Fludarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Cytarabine | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Selinexor | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Venetoclax | Other | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Matching Placebo for selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Matching Placebo for selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Matching Placebo for selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Matching Placebo for selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Matching Placebo for selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Matching Placebo for selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Matching Placebo for selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Matching Placebo for selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Matching Placebo for selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Matching Placebo for selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Matching Placebo for selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Selinexor | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Biospecimen Collection | PROCEDURE | Phase PHASE1 | Relapsed Myelodysplastic Syndrome | RECRUITING | NCT06399640 |
| Bone Marrow Aspiration and Biopsy | PROCEDURE | Phase PHASE1 | Relapsed Myelodysplastic Syndrome | RECRUITING | NCT06399640 |
| Eltanexor | DRUG | Phase PHASE1 | Relapsed Myelodysplastic Syndrome | RECRUITING | NCT06399640 |
| Paclitaxel | DRUG | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT05983276 |
| Decitabine | DRUG | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT05983276 |
| Momelotinib | DRUG | Phase PHASE2 | Myelofibrosis | RECRUITING | NCT05980806 |
| Pacritinib | DRUG | Phase PHASE2 | Myelofibrosis | NOT_YET_RECRUITING | NCT07447817 |
| Matching Placebo for selinexor | DRUG | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT05611931 |
| Irinotecan | DRUG | Phase PHASE1 | Solid Tumor Malignancy | WITHDRAWN | NCT05177276 |
| Elotuzumab, Selinexor, and Dexamethasone (ESd) | DRUG | Phase PHASE2 | Relapsed Multiple Myeloma | WITHDRAWN | NCT05170789 |
| Atezolizumab | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT05093608 |
| Selinexor Pill | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT05093608 |
| Methotrexate | DRUG | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Filgrastim | BIOLOGICAL | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Tipiracil | DRUG | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT04854434 |
| Trifluridine | DRUG | Phase PHASE2 | Metastatic Colorectal Cancer | TERMINATED | NCT04854434 |
| Dexamethasone Oral | DRUG | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05028348 |
| Lenalidomide capsule | DRUG | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04717700 |
| Bortezomib Injection | DRUG | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04717700 |
| Selinexor 20 MG Oral Tablet | DRUG | Phase PHASE2 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT04717700 |
| Selinexor 100 MG | DRUG | Phase PHASE2 | Multiple Myeloma | SUSPENDED | NCT04661137 |
| Selinexor 80 MG | DRUG | Phase PHASE2 | Multiple Myeloma | SUSPENDED | NCT04661137 |
| Selinexor 60 MG | DRUG | Phase PHASE2 | Multiple Myeloma | SUSPENDED | NCT04661137 |
| Tafasitamab | DRUG | Phase PHASE1 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT04607772 |
| Polatuzumab Vedotin | DRUG | Phase PHASE1 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT04607772 |
| Bendamustine | DRUG | Phase PHASE1 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT04607772 |
| Physician's Choice Treatment | OTHER | Phase PHASE2 | Myelofibrosis | ACTIVE_NOT_RECRUITING | NCT04562870 |
| Ruxolitinib | DRUG | Phase PHASE2 | Myelofibrosis | RECRUITING | NCT05980806 |
| Methylprednisolone | DRUG | Phase PHASE1 | Refractory Multiple Myeloma | RECRUITING | NCT04519476 |
| Placebo matching for Selinexor (continuous therapy) | DRUG | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | RECRUITING | NCT04442022 |
| Selinexor (continuous therapy) | DRUG | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | RECRUITING | NCT04442022 |
| Cisplatin (combination therapy) | DRUG | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | RECRUITING | NCT04442022 |
| Dexamethasone (combination therapy) | DRUG | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | RECRUITING | NCT04442022 |
| Gemcitabine (combination therapy) | DRUG | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | RECRUITING | NCT04442022 |
| Rituximab (combination therapy) | DRUG | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | RECRUITING | NCT04442022 |
| Placebo matching for Selinexor (combination therapy) | DRUG | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | RECRUITING | NCT04442022 |
| Selinexor (combination therapy) | DRUG | Phase PHASE2 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | RECRUITING | NCT04442022 |
| Carmustine | DRUG | Phase PHASE1 | Glioblastoma Multiforme | TERMINATED | NCT04421378 |
| TTField | DEVICE | Phase PHASE1 | Glioblastoma Multiforme | TERMINATED | NCT04421378 |
| Bevacizumab | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | TERMINATED | NCT05093608 |
| Standard Fractionated Radiation therapy (RT) | RADIATION | Phase PHASE1 | Glioblastoma Multiforme | TERMINATED | NCT04421378 |
| Lomustine (CCNU) | DRUG | Phase PHASE1 | Glioblastoma Multiforme | TERMINATED | NCT04421378 |
| Temozolomide (TMZ) | DRUG | Phase PHASE1 | Glioblastoma Multiforme | TERMINATED | NCT04421378 |
| Selinexor 60 mg | DRUG | Phase PHASE2 | Myelofibrosis | RECRUITING | NCT05980806 |
| Selinexor 80 mg | DRUG | Phase PHASE1 | Non-Small Cell Lung Carcinoma (NSCLC) | COMPLETED | NCT04256707 |
| Selinexor 40 mg | DRUG | Phase PHASE2 | Myelofibrosis | RECRUITING | NCT05980806 |
| FOLFIRI | DRUG | Phase PHASE1 | Non-Small Cell Lung Carcinoma (NSCLC) | COMPLETED | NCT04256707 |
| Selinexor 100 mg | DRUG | Phase PHASE1 | Non-Small Cell Lung Carcinoma (NSCLC) | COMPLETED | NCT04256707 |
| Venetoclax | DRUG | Phase PHASE1 | Relapsed Myelodysplastic Syndrome | RECRUITING | NCT06399640 |
| Matching placebo for selinexor | DRUG | Phase PHASE3 | Endometrial Cancer | ACTIVE_NOT_RECRUITING | NCT03555422 |
| Open Label Selinexor | DRUG | Phase PHASE2 | Thymoma | TERMINATED | NCT03193437 |
| Pembrolizumab | BIOLOGICAL | Phase PHASE1 | Advanced Urothelial Carcinoma | TERMINATED | NCT04856189 |
| Doxorubicin | DRUG | Phase PHASE1 | Soft Tissue Sarcoma | COMPLETED | NCT03042819 |
| Fosaprepitant | DRUG | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02780609 |
| Autologous Hematopoietic Cell Transplantation (HCT) | PROCEDURE | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02780609 |
| Melphalan | DRUG | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02780609 |
| Nivolumab | DRUG | Phase PHASE1 | Solid Tumors | TERMINATED | NCT02702492 |
| Niacin ER | DRUG | Phase PHASE1 | Solid Tumors | TERMINATED | NCT02702492 |
| KPT-9274 | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT04914845 |
| ASTX727 | DRUG | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma (RRMM) | COMPLETED | NCT02649790 |
| KPT-8602 | DRUG | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma (RRMM) | COMPLETED | NCT02649790 |
| carfilzomib | DRUG | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT02628704 |
| Placebo (for selinexor) | DRUG | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT02628704 |
| Docetaxel | DRUG | Phase PHASE1 | Non-Small Cell Lung Carcinoma (NSCLC) | COMPLETED | NCT04256707 |
| Sorafenib | DRUG | Phase PHASE1 | Leukemia | COMPLETED | NCT02530476 |
| Ifosfamide | DRUG | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT02471911 |
| Carboplatin | DRUG | Phase PHASE2 | Ovarian Cancer | RECRUITING | NCT05983276 |
| Etoposide | DRUG | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT02471911 |
| Cyclophosphamide | DRUG | Phase PHASE1 | Myeloma Multiple | WITHDRAWN | NCT03191981 |
| Mesna | DRUG | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT02436707 |
| Cisplatin | DRUG | Phase PHASE1 | B-cell Lymphoma | COMPLETED | NCT02741388 |
| Gemcitabine | DRUG | Phase PHASE1 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT04607772 |
| Rituximab | DRUG | Phase PHASE1 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT04607772 |
| Placebo | OTHER | Phase PHASE3 | Myelofibrosis | ACTIVE_NOT_RECRUITING | NCT04562389 |
| Verdinexor | DRUG | Phase PHASE1 | Healthy | TERMINATED | NCT02431364 |
| Bone marrow biopsy | PROCEDURE | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02416908 |
| G-CSF | DRUG | Phase PHASE2 | Lymphoma | ACTIVE_NOT_RECRUITING | NCT02436707 |
| Cladribine | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02416908 |
| Daunorubicin | DRUG | Phase PHASE1 | Leukemia | COMPLETED | NCT02403310 |
| Folinic Acid | DRUG | Phase PHASE1 | Colorectal Neoplasm | TERMINATED | NCT02384850 |
| 5-FU | DRUG | Phase PHASE1 | Colorectal Neoplasm | TERMINATED | NCT02384850 |
| Oxaliplatin | DRUG | Phase PHASE1 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT04607772 |
| Vehicle Gel | OTHER | Phase PHASE1 | Diabetic Foot Ulcers | WITHDRAWN | NCT02367690 |
| Standard-of-Care | OTHER | Phase PHASE1 | Diabetic Foot Ulcers | WITHDRAWN | NCT02367690 |
| Mezigdomide | DRUG | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT02343042 |
| Belantamab Mafodotin | DRUG | Phase PHASE1 | Multiple Myeloma | RECRUITING | NCT02343042 |
| Clarithromycin | DRUG | Phase PHASE2 | Myeloma Multiple | TERMINATED | NCT04843579 |
| Elotuzumab | DRUG | Phase PHASE3 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT05028348 |
| Ixazomib | DRUG | Phase PHASE1 | Liposarcoma | WITHDRAWN | NCT03880123 |
| Carfilzomib | DRUG | Phase PHASE2 | Multiple Myeloma in Relapse | ACTIVE_NOT_RECRUITING | NCT04925193 |
| Daratumumab | DRUG | Phase PHASE2 | Multiple Myeloma in Relapse | ACTIVE_NOT_RECRUITING | NCT04925193 |
| Bortezomib | DRUG | Phase PHASE2 | Multiple Myeloma, Refractory | RECRUITING | NCT04414475 |
| Pomalidomide | DRUG | Phase PHASE2 | Multiple Myeloma in Relapse | ACTIVE_NOT_RECRUITING | NCT04925193 |
| Lenalidomide | DRUG | Phase PHASE2 | Multiple Myeloma | WITHDRAWN | NCT05820763 |
| Laboratory Biomarker Analysis | OTHER | Phase PHASE1 | Recurrent Squamous Cell Lung Carcinoma | WITHDRAWN | NCT02536495 |
| Pharmacological Study | OTHER | Phase PHASE1 | Recurrent Squamous Cell Lung Carcinoma | WITHDRAWN | NCT02536495 |
| Ibrutinib | DRUG | Phase PHASE1 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | WITHDRAWN | NCT04607772 |
| cytarabine | DRUG | Phase PHASE1 | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | COMPLETED | NCT02299518 |
| etoposide | DRUG | Phase PHASE1 | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | COMPLETED | NCT02299518 |
| mitoxantrone hydrochloride | DRUG | Phase PHASE1 | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | COMPLETED | NCT02299518 |
| Idarubicin | DRUG | Phase PHASE2 | Acute Myeloid Leukemia (Relapsed/Refractory) | COMPLETED | NCT02249091 |
| selinexor (KPT-330) | DRUG | Phase PHASE2 | Myelodysplastic Syndromes | COMPLETED | NCT02228525 |
| Selinexor (KPT-330) | DRUG | Phase PHASE2 | Squamous Cell Carcinoma | TERMINATED | NCT02213133 |
| methotrexate/hydrocortisone/cytarabine | DRUG | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Cytarabine | DRUG | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Fludarabine | DRUG | Phase PHASE1 | Acute Leukemia of Ambiguous Lineage in Relapse | ACTIVE_NOT_RECRUITING | NCT04898894 |
| Dexamethasone | DRUG | Phase PHASE2 | Multiple Myeloma in Relapse | ACTIVE_NOT_RECRUITING | NCT04925193 |
| Liposomal doxorubicin | DRUG | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT02186834 |
| dose-escalated selinexor treatment | DRUG | Phase PHASE1 | Rectal Neoplasms | UNKNOWN | NCT02137356 |
| standard dose capecitabine | DRUG | Phase PHASE1 | Rectal Neoplasms | UNKNOWN | NCT02137356 |
| standard dose pelvic radiation therapy | RADIATION | Phase PHASE1 | Rectal Neoplasms | UNKNOWN | NCT02137356 |
| Correlative studies | OTHER | Phase PHASE1 | Recurrent Melanoma | COMPLETED | NCT02120222 |
| laboratory biomarker analysis | OTHER | Phase PHASE1 | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | COMPLETED | NCT02299518 |
| pharmacological study | OTHER | Phase PHASE1 | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | COMPLETED | NCT02299518 |
| selinexor | DRUG | Preclinical | Multiple Myeloma | AVAILABLE | NCT07215832 |
| decitabine | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | COMPLETED | NCT02093403 |
| Ara-C | DRUG | Phase PHASE2 | Acute Myeloid Leukemia (AML) | COMPLETED | NCT02088541 |
| Hydroxyurea | DRUG | Phase PHASE2 | Acute Myeloid Leukemia (AML) | COMPLETED | NCT02088541 |
| KCP-330 | DRUG | Phase PHASE1 | Sarcoma | COMPLETED | NCT01896505 |
| Acetaminophen | DRUG | Phase PHASE1 | Solid Tumor | COMPLETED | NCT01607905 |
| Selinexor | DRUG | Phase PHASE2 | Multiple Myeloma in Relapse | ACTIVE_NOT_RECRUITING | NCT04925193 |
| KPT-330 | DRUG | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | COMPLETED | NCT02471911 |
Total products: 687